According to a research report this morning, Canaccord Genuity decreases its PT on Delcath Systems DCTH from $8 to $5.
Canaccord Genuity explained, ‘These physicians provided an interesting perspective about how CHEMOSAT fits in the oncology armamentarium. We reduce our forward estimates and price target – to $5.00 from $8.00 – to reflect dilution related to the recent equity offering and previously announced delay of the NDA filing (mid-August-E).”
Delcath Systems closed Friday at $1.44 as Canaccord Genuity maintains its Buy rating.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in